EQL Pharma AB is a Sweden-based Company that operates as a generic drugs and specialty pharmaceutical company. The Company engages in marketing, distributing, and selling generic drugs and specialty pharmaceuticals. Its main products are Anastrozol, Venlafaxin, Carvedilol, Metformin, Sumatriptan, Mometason, Glepark, among others. The company operates in Sweden and in Scandinavia.

Employees

Sector

Drug Retailers

Calendar

11-05 Earnings release - Q2 2027

More about the company

Quotes

Date	Price	Change	Volume
26-10-20	SEK 20.25	-4.71%	68,551
26-10-19	SEK 21.25	-3.41%	44,894
26-10-16	SEK 22.00	-3.08%	21,902
26-10-15	SEK 22.70	-0.66%	6,620
26-10-14	SEK 22.85	+2.24%	11,833

Delayed Quote Nasdaq Stockholm

More quotes

EPS Estimates

Evolution of Analysts' Estimates - EPS - EQL Pharma AB

Revisions to estimates

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - EQL Pharma AB

Company calendar

Market Closed - Nasdaq Stockholm 12:00:00 2026-10-20 EDT			5-day change	1st Jan Change
20.25 ^SEK	-4.71%		-9.40%	-64.97%

08-20	EQL Pharma AB Appoints Niraj Kumar as New Board Member	CI
08-17	EQL Pharma CFO Allan Sylvest Aasberg makes his first share purchase	FW

Market Cap	598M 60.41M 53.77M 49.83M 45.16M 84.87M 5.72B 86.29M 235M 2.99B 227M 222M 9.55B	P/E 2027 *	-	P/E 2028 *	8.47x
Enterprise Value	1.01B 103M 91.27M 84.59M 76.65M 144M 9.71B 146M 399M 5.08B 385M 377M 16.22B	EV / Sales 2027 *	2.09x	EV / Sales 2028 *	1.68x
Free-Float	42.3%	Yield 2027 *	-	Yield 2028 *	-

Markets		Quality
Nasdaq Stockholm	EQL	Delayed
Deutsche Boerse AG	7JK	End-of-day quote
Deutsche Boerse AG	7JK	Delayed
Börse Stuttgart	7JK	Delayed
Boerse Muenchen	7JK	Real-time

08-20	EQL Pharma AB Appoints Niraj Kumar as New Board Member	CI
08-17	EQL Pharma CFO Allan Sylvest Aasberg makes his first share purchase	FW
08-14	DNB Carnegie raises its justified value for EQL Pharma	FW
08-12	EQL Pharma Enters UTI Treatment License Deal in Hungary	MT
08-12	EQL Pharma: Analysguiden cuts fair value estimate to 38 kronor	FW
08-12	EQL Pharma licenses Memprex to partner in Hungary	FW
08-12	EQL Pharma AB Licenses Memprex for Sale in Hungary	CI
08-07	EQL Pharma AB, Q1 2027 Earnings Call, Aug 07, 2026
08-07	EQL Pharma AB Reports Earnings Results for the First Quarter Ended June 30, 2026	CI
08-07	EQL Pharma swings to an operating loss, 'going through a tough period' - CEO (update)	FW
08-07	EQL Pharma swings to an operating loss, 'going through a tough period' - CEO	FW
08-07	Eql Pharma AB Provides Earnings Guidance for the Year 2026/27	CI
07-28	DNB Carnegie cuts justified value for EQL Pharma	FW

EQL Pharma AB Stock

Stocks

EQL

SE0005497732

Drug Retailers

Valuation: EQL Pharma AB

Chart: EQL Pharma AB

Latest news: EQL Pharma AB

Last Transcript: EQL Pharma AB

Analysts' recommendations: EQL Pharma AB

Press Releases: EQL Pharma AB

Quotes and Performance

Price Extremes

Managers and Directors: EQL Pharma AB

Latest insider transactions

Other Drug Retailers

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise

08-20	Bulletin from the annual general meeting in EQL Pharma AB on 20 August 2026	AQ
08-14	EQL Pharma: Improvement emerging, confirmation needed – Q1 review	AQ
08-12	Memprex© (methenamine hippurate) license signed with partner for Hungary	AQ
08-07	EQL Pharma: Soft start as expected, guidance intact	AQ
08-07	Interim Report April - June 2026	AQ

1 day	-4.71%
1 week	-9.40%
Current month	-11.96%
1 month	-13.46%
3 months	-0.49%
6 months	-62.84%
Current year	-64.97%

1 week	19.7	22.95
1 month	19.7	28.8
Current year	17.38	67.5
1 year	17.38	67.5
3 years	17.38	98.6
5 years	17.38	98.6
10 years	6.45	98.6

Manager	Title	Age	Since
Axel Schörling CEO	Chief Executive Officer	40	2022-08-16
Allan Sylvest Aasberg DFI	Director of Finance/CFO	51	2026-03-31
Martin Kristofferson COO	Chief Operating Officer	48	2022-08-16

Director	Title	Age	Since
Lars Christer Fedrik Fåhraeus CHM	Chairman	61	2022-08-16
Anders Månsson CHM	Chairman	59	-
Ingrid Linda Marie Neckmar BRD	Director/Board Member	53	2019-12-31

Date	Insider	Type	Main position	Quantity	% Market Cap.
8/14/26	Allan Sylvest Aasberg	Buy	Chief Financial Officer	20,000	0.0677%
3/27/26	Axel Schörling	Sell	Chief Executive Officer	24,066	0.0815%
12/30/25	Magnus Erreth	Buy	Executive/Senior Manager	1,000	0.0034%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EQL PHARMA AB	-4.71%	-9.40%	-66.25%	-23.30%	63.36M
JD HEALTH INTERNATIONAL INC.	+3.22%	+10.37%	-34.49%	+11.02%	15.67B
RAIA DROGASIL S.A.	+17.93%	+4.69%	+13.42%	-15.26%	7.38B
TSURUHA HOLDINGS INC.	+1.67%	+6.36%	-9.42%	+7.24%	6.36B
MATSUKIYOCOCOKARA & CO.	+1.21%	+4.81%	-10.44%	-0.38%	6.37B
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED	+1.50%	+7.02%	-48.48%	-32.97%	6.19B
YIFENG PHARMACY CHAIN CO., LTD.	+1.62%	+3.16%	+4.37%	-4.61%	4.6B
CLICKS GROUP LIMITED	+0.74%	+12.56%	-33.86%	-0.05%	3.44B
COSMOS PHARMACEUTICAL CORPORATION	+1.30%	+2.36%	-12.90%	-8.26%	3.23B
DASHENLIN PHARMACEUTICAL GROUP CO., LTD.	-4.30%	-4.95%	+4.29%	-21.47%	3.25B
Average	+2.02%	+1.05%	-19.38%	-8.80%	5.66B
Weighted average by Cap.	+3.73%	+2.94%	-17.62%	-3.88%

	2027 *	2028 *
Net sales	486M 49.15M 43.75M 40.54M 36.74M 69.05M 4.66B 70.2M 191M 2.44B 184M 181M 7.77B	612M 61.88M 55.08M 51.05M 46.26M 86.93M 5.86B 88.39M 241M 3.07B 232M 227M 9.79B
Net income	-	71M 7.17M 6.38M 5.92M 5.36M 10.08M 679M 10.25M 27.89M 356M 26.91M 26.35M 1.13B
Net Debt	417M 42.13M 37.5M 34.75M 31.49M 59.18M 3.99B 60.17M 164M 2.09B 158M 155M 6.66B	430M 43.44M 38.67M 35.84M 32.47M 61.03M 4.12B 62.05M 169M 2.15B 163M 160M 6.87B